(Q33927979)

English

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Larry Norton

12

0 references

13

object named as

Hyman Muss

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Gretchen G Kimmick

10

object named as

Gretchen Kimmick

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

6

object named as

Ruth O'Regan

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

5

object named as

Edith A Perez

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Constance T Cirrincione

3

object named as

Constance T Cirrincione

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Lawrence N Shulman

1

object named as

Lawrence N Shulman

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Clifford A Hudis

14

object named as

Clifford A Hudis

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

15

object named as

Eric P Winer

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2

object named as

Donald A Berry

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Heather P Becker

4

object named as

Heather P Becker

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Silvana Martino

7

object named as

Silvana Martino

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Charles L Shapiro

8

object named as

Charles L Shapiro

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Charles J Schneider

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Harold J Burstein

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

16 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2311-2317

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105484

5 July 2018

Adjuvant docetaxel for high-risk, node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105484

5 July 2018

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105484

5 July 2018

Effect of screening and adjuvant therapy on mortality from breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105484

5 July 2018

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105484

29 October 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105484

29 October 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105484

29 October 2018

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105484

29 October 2018

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105484

29 October 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105484

29 October 2018

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://pubmed.ncbi.nlm.nih.gov/24934787

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

https://pubmed.ncbi.nlm.nih.gov/24934787

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2013.53.7142

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33927979&oldid=1872228106"